Aldevron Launches Eureca-V MAD7 at Advanced Therapies Week

Anna Osborne
20 January 2023
Automation & Digitisation
Cell Therapy
Global leader in custom development and manufacturing for Biotech Aldevron, has announced the launch of Eureca-VTM Nuclease, a wild-type MAD7 CRISPR Type-V nuclease, at Phacilitate’s Advanced Therapies Week, Miami Convention Centre, 17th-20th January 2023.

Eureca-V, launched at research grade today with GMP to follow, has been licensed to Aldevron from Inscripta and will be the Company’s third GMP CRISPR nuclease and the first Type-V nuclease available as a GMP catalogue product.

“We are thrilled to offer Eureca-V product at research grade starting today, and later this year, our clients can expect a smooth transition to our GMP product,” said Venkata Indurthi, CSO at Aldevron

The technology works to ensure the acceleration of translational CRISPR research and will support academic and commercial researchers investigating a wild-type Type-V CRISPR nuclease that targets T-rich regions of the genome.

The launch of Eureca-V Nuclease expands Aldevron’s CRISPR nuclease offerings for therapeutic, diagnostic and agricultural workflows. The pass-through license for research use accompanying the purchase of this platform will enable clients to thoroughly evaluate the product without committing to long-term agreements.


How are you enjoying this news article? Let us know your thoughts, here >>


“Aldevron’s extensive history in CRISPR nucleases allows researchers to develop therapies that will eventually address global health issues,” added Venkata.

The Company’s CRISPR nuclease portfolio is applied in preclinical and clinical research worldwide – as they lead in the supply of critical raw materials and reagents foe cell and gene therapies.

Advanced Therapies Week 2023 provided the stage for Aldervon’s announcement of this news, as cell and gene therapy industry experts came together to share knowledge and insight. Located on the exhibit floor the Company team were available to share and discuss the capabilities this new tech will offer clients.  

“The availability of Eureca-V drives forward the entire genomics medicine industry and enhances Aldevron’s position as a supplier of choice for CRISPR drug substances and drug products,” said Tom Foti, Vice President and General Manager of Aldevron’s Protein Business Unit.

Source: Aldevron Press Release


While we have you…

We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to